INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin Lymphoma Culver City, November 3, 2016 NantKwest Inc.
View HTML
Toggle Summary NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology
Oral Presentation to Highlight Preclinical Data on a Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cell Therapy (CD19.taNK) in CD Resistant B-Cell Non-Hodgkin Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
View HTML
Toggle Summary NantKwest to Present Data on the First Next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference
Positive Preclinical Data Of The First “Off The Shelf,” GMP-Grade, IL-2-Independent NK Cell Line Expressing The High-Affinity Fc-Receptor To Augment Antibody Therapeutics CULVER CITY, Calif.  –  April 15, 2016  - NantKwest Inc.
View HTML
Toggle Summary NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
Novel Trispecific CD19.t-haNK TM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the
View HTML
Toggle Summary NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions CULVER CITY, Calif. --(BUSINESS WIRE)--May 31, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage,
View HTML
Toggle Summary Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 13, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, today announced that
View HTML
Toggle Summary NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease
First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initiated For Pancreatic, Lung, Breast, Colon, Melanoma, Sarcoma, Chordoma, Head And Neck, Non Hodgkin’s Lymphoma, Merkel Cell And Ovarian Cancers. First Whole Genome, Transcriptomic, Proteomic (GPS Cancer) Informed
View HTML
Toggle Summary Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA
Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks , the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr.
View HTML
Toggle Summary Partnership enables rapid and efficient start-up of 15,000 research sites nationwide
CULVER CITY, Calif. – March 22, 2016 – Cancer Moonshot 2020 , the nation's most comprehensive cancer collaborative initiative formed to accelerate next-generation immunotherapy in cancer, announced today the selection of Schulman IRB as its national institutional review board (IRB) of record.
View HTML
Toggle Summary Patrick Soon-Shiong, MD, to Deliver Cancer Moonshot 2020 Keynote at Biocom Global Life Science Partnering Conference
La Jolla, CA – February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks , LLC, and leader of the Cancer MoonShot 2020 program, will deliver the keynote session, “Cancer Moonshot 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science
View HTML